200,000+ products from a single source!
sales@angenechem.com
145739-56-6 | 2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]-
CAS No: 145739-56-6 Catalog No: AG001DD5 MDL No:
Product Description
Catalog Number:
AG001DD5
Chemical Name:
2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]-
CAS Number:
145739-56-6
Molecular Formula:
C19H18N2O4S
Molecular Weight:
370.4222
IUPAC Name:
6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid
InChI:
InChI=1S/C19H18N2O4S/c1-3-24-16-9-8-12(10-17(16)25-4-2)18-21-15(11-26-18)13-6-5-7-14(20-13)19(22)23/h5-11H,3-4H2,1-2H3,(H,22,23)
InChI Key:
XDBHURGONHZNJF-UHFFFAOYSA-N
SMILES:
CCOc1cc(ccc1OCC)c1scc(n1)c1cccc(n1)C(=O)O
UNII:
S6RXB5KF56
Properties
Complexity:
467
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
370.099g/mol
Formal Charge:
0
Heavy Atom Count:
26
Hydrogen Bond Acceptor Count:
7
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
370.423g/mol
Monoisotopic Mass:
370.099g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
110A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.8
Literature
| Title | Journal |
|---|---|
| Phosphodiesterase inhibitors in inflammatory bowel disease. | Expert opinion on investigational drugs 20120301 |
| Tetomilast attenuates elastase-induced pulmonary emphysema through inhibition of oxidative stress in rabbits. | Biological & pharmaceutical bulletin 20120101 |
| Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review. | Current pharmaceutical design 20100101 |
| Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. | Inflammatory bowel diseases 20081101 |
| Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? | British journal of pharmacology 20081001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070901 |
| A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. | Gastroenterology 20070101 |
| Tetomilast. | IDrugs : the investigational drugs journal 20050601 |
| Medical therapy for ulcerative colitis: the state of the art and beyond. | Current gastroenterology reports 20041201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20041201 |
| Digestive Disease Week 2004. Bowel inflammation. | IDrugs : the investigational drugs journal 20040601 |
| Effects of OPC-6535 on lipopolysaccharide-induced acute liver injury in the rat: involvement of superoxide and tumor necrosis factor-alpha from hepatic macrophages. | Surgery 20031101 |
| A practical synthesis of 3,4-diethoxybenzthioamide based on Friedel-Crafts reaction with potassium thiocyanate in methanesulfonic acid. | Bioorganic & medicinal chemistry letters 20020902 |
| OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability. | Free radical biology & medicine 20010201 |
| OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury. | The Journal of surgical research 19970901 |
| Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. | Journal of medicinal chemistry 19950120 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.